ESC Premium Access

Hot Line Session 3

Event: ESC Congress 2018
Topic: Other
Session type: Late-Breaking Science
Date: 27 August 2018
Time: 11:00 - 12:30

Session

20 presentations in this session

Opening question - ATTR-ACT Trial.

Thumbnail

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Speaker: Professor C. Rapezzi (Ferrara, IT)
Thumbnail

Discussant review - ATTR-ACT.

Speaker: Professor J. George (Rehovot, IL)
Thumbnail

Questions from the audience and discussion.

Thumbnail

Concluding question - ATTR-ACT Trial.

Thumbnail

Opening question - COMMANDER HF.

Thumbnail

COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Thumbnail

Discussant review - COMMANDER HF.

Speaker: Doctor J. Tardif (Montreal, CA)
Thumbnail

Questions from the audience and discussion.

Thumbnail

Concluding question - COMMANDER HF.

Thumbnail

8 speakers from this session

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)
26 presentations
0 follower

Professor Jacob George

Kaplan Medical Center, Rehovot (Israel)
2 presentations
0 follower

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)
69 presentations
0 follower

Doctor Jean-Claude Tardif

Montreal Heart Institute, Montreal (Canada)
5 presentations
0 follower

Professor Jean-Francois Obadia

Civils Hospices of Lyon, Lyon (France)
9 presentations
0 follower

Professor Stephan Windecker

Bern University Hospital, Inselspital, Bern (Switzerland)
29 presentations
4 followers

Professor Patrick Washington Serruys

National University of Ireland, Galway (Ireland)
14 presentations
0 follower

Professor Adnan Kastrati

German Heart Center Muenchen Technical University of Munich, Munich (Germany)
9 presentations
0 follower

This platform is supported by

logo Novo Nordisk